<?xml version="1.0" encoding="UTF-8"?>
<billStatus>
  <bill>
    <committees>
      <billCommittees>
        <item>
          <activities>
            <item>
              <name>Referred to</name>
              <date>2015-03-13T15:00:39Z</date>
            </item>
          </activities>
          <name>Energy and Commerce Committee</name>
          <chamber>House</chamber>
          <systemCode>hsif00</systemCode>
          <subcommittees>
            <item>
              <activities>
                <item>
                  <name>Referred to</name>
                  <date>2015-03-20T19:34:01Z</date>
                </item>
              </activities>
              <name>Health Subcommittee</name>
              <systemCode>hsif14</systemCode>
            </item>
          </subcommittees>
          <type>Standing</type>
        </item>
      </billCommittees>
    </committees>
    <summaries>
      <billSummaries>
        <item>
          <actionDate>2015-03-13</actionDate>
          <lastSummaryUpdateDate>2015-07-02T22:05:13Z</lastSummaryUpdateDate>
          <updateDate>2015-03-13T04:00:00Z</updateDate>
          <versionCode>00</versionCode>
          <actionDesc>Introduced in House</actionDesc>
          <text><![CDATA[<p><b>Promoting Access for Treatments Ideal in Enhancing New Therapies Act of 2015 or the PATIENT Act of 2015</b></p> <p>This bill amends the Federal Food, Drug, and Cosmetic Act to extend to five years the three-year marketing exclusivity period provided to certain new drugs that include an active ingredient that was already approved by the Food and Drug Administration.</p> <p>A drug is provided this extended exclusivity period if it is approved for a new indication or use, or the drug has been reformulated or redesigned to:</p> <ul> <li>promote greater patient adherence to an approved treatment regime,</li> <li>reduce the public health risks associated with the drug,</li> <li>reduce side effects or adverse events,</li> <li>provide benefits to the health-care system, or</li> <li> provide other comparable patient benefits. </li> </ul>]]></text>
          <name>Introduced in House</name>
        </item>
      </billSummaries>
    </summaries>
    <sponsors>
      <item>
        <identifiers>
          <bioguideId>B001257</bioguideId>
          <lisID>1838</lisID>
          <gpoId>7881</gpoId>
        </identifiers>
        <fullName>Rep. Bilirakis, Gus M. [R-FL-12]</fullName>
        <state>FL</state>
        <lastName>Bilirakis</lastName>
        <byRequestType />
        <firstName>Gus</firstName>
        <middleName>M.</middleName>
        <bioguideId>B001257</bioguideId>
        <district>12</district>
        <party>R</party>
      </item>
    </sponsors>
    <notes />
    <createDate>2015-03-14T04:46:25Z</createDate>
    <recordedVotes />
    <constitutionalAuthorityStatementText><![CDATA[<pre>[Congressional Record Volume 161, Number 43 (Friday, March 13, 2015)]From the Congressional Record Online through the Government Publishing Office [<a href='http://www.gpo.gov'>www.gpo.gov</a>]By Mr. BILIRAKIS:H.R. 1353.Congress has the power to enact this legislation pursuantto the following:Article I, Section 8, Clause 1, which gives the Congressthe authority to provide for the general welfare of theUnited States. Additionally, under Article I, Section 8,Clause 8 which gives Congress the power to promote theprogress of science and useful arts by securing for limitedtimes to authors and inventors the exclusive right to theirrespective writings and discoveries[Page H1635]</pre>]]></constitutionalAuthorityStatementText>
    <actions>
      <actionTypeCounts>
        <billReferrals>1</billReferrals>
        <introducedInTheHouse>1</introducedInTheHouse>
        <placeholderTextForH>1</placeholderTextForH>
        <introducedInHouse>1</introducedInHouse>
      </actionTypeCounts>
      <item>
        <actionDate>2015-03-20</actionDate>
        <committee>
          <name>Health Subcommittee</name>
          <systemCode>hsif14</systemCode>
        </committee>
        <links />
        <sourceSystem>
          <name>House committee actions</name>
          <code>1</code>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionCode>H11100</actionCode>
        <committee>
          <name>Energy and Commerce Committee</name>
          <systemCode>hsif00</systemCode>
        </committee>
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <links />
        <type>IntroReferral</type>
        <sourceSystem>
          <name>House floor actions</name>
          <code>2</code>
        </sourceSystem>
        <actionDate>2015-03-13</actionDate>
      </item>
      <item>
        <actionCode>Intro-H</actionCode>
        <committee />
        <text>Introduced in House</text>
        <links />
        <type>IntroReferral</type>
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
        <actionDate>2015-03-13</actionDate>
      </item>
      <item>
        <actionCode>1000</actionCode>
        <committee />
        <text>Introduced in House</text>
        <links />
        <type>IntroReferral</type>
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
        <actionDate>2015-03-13</actionDate>
      </item>
      <actionByCounts>
        <houseOfRepresentatives>4</houseOfRepresentatives>
      </actionByCounts>
    </actions>
    <congress>114</congress>
    <originChamber>House</originChamber>
    <introducedDate>2015-03-13</introducedDate>
    <subjects>
      <billSubjects>
        <legislativeSubjects>
          <item>
            <name>Administrative law and regulatory procedures</name>
          </item>
          <item>
            <name>Department of Health and Human Services</name>
          </item>
          <item>
            <name>Drug safety, medical device, and laboratory regulation</name>
          </item>
          <item>
            <name>Prescription drugs</name>
          </item>
        </legislativeSubjects>
        <policyArea>
          <name>Health</name>
        </policyArea>
      </billSubjects>
    </subjects>
    <billNumber>1353</billNumber>
    <billType>HR</billType>
    <title>PATIENT Act of 2015</title>
    <laws />
    <cosponsors>
      <item>
        <district>11</district>
        <state>VA</state>
        <fullName>Rep. Connolly, Gerald E. [D-VA-11]</fullName>
        <firstName>Gerald</firstName>
        <middleName>E.</middleName>
        <party>D</party>
        <sponsorshipDate>2015-03-13</sponsorshipDate>
        <lastName>Connolly</lastName>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <identifiers>
          <gpoId>8202</gpoId>
          <lisID>1959</lisID>
          <bioguideId>C001078</bioguideId>
        </identifiers>
        <sponsorshipWithdrawnDate />
        <bioguideId>C001078</bioguideId>
      </item>
      <item>
        <district>3</district>
        <state>NY</state>
        <fullName>Rep. Israel, Steve [D-NY-3]</fullName>
        <firstName>STEVE</firstName>
        <middleName />
        <party>D</party>
        <sponsorshipDate>2015-03-13</sponsorshipDate>
        <lastName>ISRAEL</lastName>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <identifiers>
          <bioguideId>I000057</bioguideId>
          <lisID>1663</lisID>
          <gpoId>8063</gpoId>
        </identifiers>
        <sponsorshipWithdrawnDate />
        <bioguideId>I000057</bioguideId>
      </item>
      <item>
        <district>9</district>
        <state>VA</state>
        <fullName>Rep. Griffith, H. Morgan [R-VA-9]</fullName>
        <firstName>H.</firstName>
        <middleName>Morgan</middleName>
        <party>R</party>
        <sponsorshipDate>2015-03-13</sponsorshipDate>
        <lastName>Griffith</lastName>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <identifiers>
          <bioguideId>G000568</bioguideId>
          <lisID>2070</lisID>
          <gpoId>8200</gpoId>
        </identifiers>
        <sponsorshipWithdrawnDate />
        <bioguideId>G000568</bioguideId>
      </item>
      <item>
        <district>5</district>
        <state>IN</state>
        <fullName>Rep. Brooks, Susan W. [R-IN-5]</fullName>
        <firstName>Susan</firstName>
        <middleName>W.</middleName>
        <party>R</party>
        <sponsorshipDate>2015-04-28</sponsorshipDate>
        <lastName>Brooks</lastName>
        <isOriginalCosponsor>False</isOriginalCosponsor>
        <identifiers>
          <lisID>2129</lisID>
          <bioguideId>B001284</bioguideId>
          <gpoId />
        </identifiers>
        <sponsorshipWithdrawnDate />
        <bioguideId>B001284</bioguideId>
      </item>
    </cosponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <version>1.0.0</version>
    <relatedBills />
    <updateDate>2018-11-21T21:22:59Z</updateDate>
    <latestAction>
      <actionDate>2015-03-20</actionDate>
      <links />
      <text>Referred to the Subcommittee on Health.</text>
    </latestAction>
    <calendarNumbers />
    <titles>
      <item>
        <titleType>Short Titles as Introduced</titleType>
        <title>PATIENT Act of 2015</title>
        <chamberCode />
        <parentTitleType />
        <chamberName />
      </item>
      <item>
        <titleType>Short Titles as Introduced</titleType>
        <title>Promoting Access for Treatments Ideal in Enhancing New Therapies Act of 2015</title>
        <chamberCode />
        <parentTitleType />
        <chamberName />
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>To amend the Federal Food, Drug, and Cosmetic Act to extend the period of exclusivity with respect to certain drugs, and for other purposes.</title>
        <chamberCode />
        <parentTitleType />
        <chamberName />
      </item>
      <item>
        <titleType>Display Title</titleType>
        <title>PATIENT Act of 2015</title>
        <chamberCode />
        <parentTitleType />
        <chamberName />
      </item>
    </titles>
    <committeeReports />
    <amendments />
    <cboCostEstimates />
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>

